OR WAIT null SECS
November 20, 2017
Ontruzant is the first biosimilar of Roche’s Herceptin (trastuzumab) to be approved in Europe.
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.
November 16, 2017
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.
November 15, 2017
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
November 13, 2017
Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.
The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.
November 10, 2017
The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for AstraZeneca’s benralizumab, a monoclonal antibody for treating severe asthma.
The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.
November 03, 2017
CDMO Celonic acquired a biomanufacturing facility in Heidelberg, Germany from Glycotope.